



**SOLBEC
PHARMACEUTICALS LTD**

19th September 2003

SALE OF CAMPERDOWN LEASES

The Company advises that it has agreed to sell its interests in the Camperdown mineral Tenements, north of Coolgardie in Western Australia to Siberia Mining Corporation Ltd. The terms of the sale, which includes all mineral rights on MLA 40/633 and all minerals except lateritic nickel on MLA 40/634, are \$25,000 cash and 1% net smelter return from production capped at \$75,000.

Released by:

Stephen Carter Managing Director Tel: (08) 9446 7555 Mob: 0412 154 029 Email: stephen.carter@solbec.com.au
--

Background Information

Solbec Pharmaceuticals Ltd is a publicly listed company on the Australian Stock exchange (code SBP).

SBP002 is a combination of two glycoalkaloids isolated from the fruit of *Solanum linnaeanum*, a weed more commonly known as Devil's Apple.

Currently the drug has completed its pre-clinical phase of trials as an anti cancer treatment. Human Phase 1 clinical trials are expected to begin later this year.

Solbec is focussing SBP002 research on treatment of mesothelioma and malignant melanoma which qualifies the drug for the fast track Orphan Drug Program.

However, under the Therapeutic Goods Administration's Special Access Scheme (SAS), SBP002 has been administered to a number of cancer patients with encouraging results. These have included: Increased well-being, Tumour size reduction, Reduced tumour growth rates, extended expected life span, Tumour eradication.

In previous studies carried out by the University of Western Australia, it was observed that SBP002-treated cells reduced the production of IL-6 when compared to the control and to cells treated with the anti-cancer drugs Gemcitabine and Docetaxol. IL-6 is known to be one of the chemicals produced by the body during disease that makes people feel unwell. IL-6 is also known to be involved in cancer cell proliferation.

As well as a range of cancers, SBP002 may be useful for treating a wide range of IL-6 related diseases. These include inflammatory diseases such as rheumatoid arthritis; microbial diseases such as HIV, chronic fatigue syndrome and malaria; heart disease such as cardiac myopathy; and other diseases such as Alzheimer's disease, arteriosclerosis, thyroiditis and Castleman's disease. Solbec has lodged patents to cover this exciting aspect of the drug's activity.

Solbec has received an Australian Government grant of \$196,000 through the Ausindustry Biotechnology Innovation Fund to carry out further research on SBP002. This research is to look at the ability of SBP002 to boost the immune system. This new line of investigation at UWA by Professor Robinson and his team represents a significant new direction for Solbec and the use of SBP002.